ClinicalTrials.gg
CompletedNCT07629310JL18008Updated Jun 11, 2026

To Evaluate the Safety of JL18008

A Phase 1 interventional study of JL18008 1 μg/kg and JL18008 5 μg/kg in HIV Infections, sponsored by Jecho Biopharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Jecho Biopharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Jun 2024, registered May 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies in HIV Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. HIV Infections · China.

Enrollment
40th of 50
40 · median 145
Started
2024
with 2 others
Phase 1
6 of 67
none open now
Registered
64th of 67
by date
Lead sponsor
2 of 67
Jecho Biopharmaceuticals Co., Ltd.

Among the 67 studies in HIV Infections with a site in China, this one is the 40th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 64th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

10 of the 67 studies in HIV Infections with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in HIV Infections with a site in China, or all of them as a file.
02

Study summary

This study is being conducted in healthy adult volunteers to evaluate the safety and tolerability of a single injection of an investigational drug called JL18008. The study also examines how the body processes the drug and how it affects immune cells. Participants receive one intramuscular injection of either JL18008 at one of six dose levels (1, 5, 10, 20, 40, or 70 μg/kg) or a placebo (an inactive substance). The study is randomized, double-blind, and placebo-controlled, meaning participants and study staff do not know who receives the active drug or placebo. Blood samples are collected over 56 days to measure drug levels, immune cell counts (such as CD4⁺ T cells), and any antibodies that may form against the drug. The goal is to find a safe dose that can be tested in future studies of people with HIV who have low CD4⁺ T cells despite antiviral treatment.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in the study, ability to understand and comply with the protocol requirements, and provision of written .
  2. Physical examination, vital signs, 12-lead , and laboratory tests (hematology, urinalysis, serum chemistry, infectious disease screening, coagulation) are normal or have no abnormality.
  3. Male or female, age 18 to 55 years inclusive.
  4. Body weight: male ≥50.0 kg, female ≥45.0 kg. (BMI) between 18.0 and 26.0 kg/m² inclusive. BMI = weight (kg) / height (m)².
  5. No clinically significant history of cardiovascular, hepatic, renal, gastrointestinal, neurological, or hematological disease.
  6. No plans for pregnancy within 6 months, and agreement to use effective with their partner from screening until 3 months after the study completion. No donation of sperm or eggs during this period.

Exclusion criteria

Exclusion Criteria:

  1. Any history of allergic disease, or food or drug allergy, that in the investigator's opinion makes the subject unsuitable for inclusion.
  2. Lactating women; women of with menstrual disorders within 90 days before dosing; women of childbearing potential who had unprotected intercourse with a male partner within 28 days before dosing.
  3. Participation in any clinical trial of an drug within 90 days before dosing, or still within the safety of a previous trial on the day of dosing.
  4. Non-physiological blood loss of ≥200 mL (including trauma, blood draw, blood donation) within 60 days before dosing, or plan to donate blood during the study or within 30 days after dosing.
  5. Any major illness considered by the investigator within 90 days before dosing.
  6. Major surgery within 60 days before dosing, or any surgery within 28 days before dosing.
  7. Fever or infectious illness within 28 days before dosing.
  8. Use of any medication (including prescription, non-prescription, herbal, or dietary supplements) within 14 days before dosing.
  9. Vaccination within 1 month before dosing, or plan to receive vaccination during the study period.
  10. History or dependence of alcohol or drug abuse, or drug use, or a positive urine drug screen at screening. Alcohol abuse defined as average weekly intake >21 standard alcohol units. One standard unit contains 14 g of alcohol (e.g., 360 mL of 5% beer, 45 mL of 40% spirits, or 120 mL of 12% wine).
  11. Daily smoking of more than 5 cigarettes within 3 months before screening, or unable to refrain from smoking during the study.
  12. Vital signs at screening meeting any of the following: systolic blood pressure \<90 mmHg or >140 mmHg; diastolic blood pressure \<50 mmHg or >90 mmHg; pulse rate \<50 beats/min or >100 beats/min.
  13. Positive test for surface antigen (HBsAg), virus antibody (HCV Ab), antibody (HIV Ab), or syphilis antibody.
  14. Clinically evident gastrointestinal, hepatic, or renal abnormality that, in the investigator's opinion, may affect drug transport, absorption, distribution, metabolism, or excretion.
  15. Any other condition that, in the investigator's judgment, might affect the study results or interfere with the subject's participation throughout the study, including but not limited to other medical history (e.g., psychiatric disorder), abnormalities in vital signs, physical examination, , or clinical laboratory tests.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Arm 1: JL18008 1 μg/kg

    Single intramuscular injection of JL18008 at 1 μg/kg.

    Drug: JL18008 1 μg/kg

  • Placebo comparator
    Arm 2: Placebo (for 1 μg/kg group)

    Single intramuscular injection of placebo (JL18008 buffer).

    Drug: Placebo (for 1 μg/kg Group)

  • Experimental
    Arm 3: JL18008 5 μg/kg

    Single intramuscular injection of JL18008 at 5 μg/kg.

    Drug: JL18008 5 μg/kg

  • Placebo comparator
    Arm 4: Placebo (for 5 μg/kg group)

    Single intramuscular injection of placebo.

    Drug: Placebo (for 5 μg/kg Group)

  • Experimental
    Arm 5: JL18008 10 μg/kg

    Single intramuscular injection of JL18008 at 10 μg/kg.

    Drug: JL18008 10 μg/kg

  • Placebo comparator
    Arm 6: Placebo (for 10 μg/kg group)

    Single intramuscular injection of placebo.

    Drug: Placebo (for 10 μg/kg Group)

  • Experimental
    Arm 7: JL18008 20 μg/kg

    Single intramuscular injection of JL18008 at 20 μg/kg.

    Drug: JL18008 20 μg/kg

  • Placebo comparator
    Arm 8: Placebo (for 20 μg/kg group)

    Single intramuscular injection of placebo.

    Drug: Placebo (for 20 μg/kg Group)

  • Experimental
    Arm 9: JL18008 40 μg/kg

    Single intramuscular injection of JL18008 at 40 μg/kg.

    Drug: JL18008 40 μg/kg

  • Placebo comparator
    Arm 10: Placebo (for 40 μg/kg group)

    Single intramuscular injection of placebo.

    Drug: Placebo (for 40 μg/kg Group)

  • Experimental
    Arm 11: JL18008 70 μg/kg

    Single intramuscular injection of JL18008 at 70 μg/kg.

    Drug: JL18008 70 μg/kg

  • Placebo comparator
    Arm 12: Placebo (for 70 μg/kg group)

    Single intramuscular injection of placebo.

    Drug: Placebo (for 70 μg/kg Group)

Interventions

  • DrugJL18008 1 μg/kg

    Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 1 μg/kg.

  • DrugJL18008 5 μg/kg

    Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 5 μg/kg.

  • DrugJL18008 10 μg/kg

    Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 10 μg/kg.

  • DrugJL18008 20 μg/kg

    Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 20 μg/kg.

  • DrugJL18008 40 μg/kg

    Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 40 μg/kg.

  • DrugJL18008 70 μg/kg

    Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 70 μg/kg.

  • DrugPlacebo (for 1 μg/kg Group)

    JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 1 μg/kg.

  • DrugPlacebo (for 5 μg/kg Group)

    JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 5 μg/kg.

  • DrugPlacebo (for 10 μg/kg Group)

    JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 10 μg/kg.

  • DrugPlacebo (for 20 μg/kg Group)

    JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 20 μg/kg.

  • DrugPlacebo (for 40 μg/kg Group)

    JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 40 μg/kg.

  • DrugPlacebo (for 70 μg/kg Group)

    JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 70 μg/kg.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by NCI CTCAE v5.0

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs). AEs graded according to NCI CTCAE version 5.0. Assessed from Day 1 through Day 56.

    Time frame: Up to 56 days

Secondary outcomes

  1. Change from Baseline in White Blood Cell Count (WBC)

    Change from baseline in white blood cell count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  2. Change from Baseline in Neutrophil Count (NEUT)

    Change from baseline in neutrophil count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  3. Change from Baseline in Eosinophil Count (EOS)

    Change from baseline in eosinophil count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  4. Change from Baseline in Basophil Count (BASO)

    Change from baseline in basophil count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  5. Change from Baseline in Lymphocyte Count (LYMPH)

    Change from baseline in lymphocyte count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  6. Change from Baseline in Red Blood Cell Count (RBC)

    Change from baseline in red blood cell count. Measured in 10¹²/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  7. Change from Baseline in Hemoglobin (HGB)

    Change from baseline in hemoglobin. Measured in g/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  8. Change from Baseline in Platelet Count (PLT)

    Change from baseline in platelet count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  9. Change from Baseline in Hematocrit (HCT)

    Change from baseline in hematocrit. Measured as a percentage (%). Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  10. Change from Baseline in Total Bilirubin (TBIL)

    Change from baseline in total bilirubin. Measured in μmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  11. Change from Baseline in Total Protein (TP)

    Change from baseline in total protein. Measured in g/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  12. Change from Baseline in Albumin (ALB)

    Change from baseline in albumin. Measured in g/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  13. Change from Baseline in Alanine Aminotransferase (ALT)

    Change from Baseline in Alanine Aminotransferase (ALT)

    Time frame: Up to 56 days

  14. Change from Baseline in Aspartate Aminotransferase (AST)

    Change from baseline in aspartate aminotransferase. Measured in U/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  15. Change from Baseline in Gamma-Glutamyl Transferase (γ-GT)

    Change from baseline in gamma-glutamyl transferase. Measured in U/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  16. Change from Baseline in Creatinine (Cr)

    Change from baseline in creatinine. Measured in μmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  17. Change from Baseline in Total Cholesterol (TCHO)

    Change from baseline in total cholesterol. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  18. Change from Baseline in Triglycerides (TG)

    Change from baseline in triglycerides. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  19. Change from Baseline in Blood Urea Nitrogen (BUN)/Urea

    Change from baseline in blood urea nitrogen. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  20. Change from Baseline in Alkaline Phosphatase (ALP)

    Change from baseline in alkaline phosphatase. Measured in U/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  21. Change from Baseline in Blood Glucose (GLU)

    Change from baseline in blood glucose. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  22. Change from Baseline in Serum Phosphorus (Pi)

    Change from baseline in serum phosphorus. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  23. Change from Baseline in Serum Sodium (Na⁺)

    Change from baseline in serum sodium. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  24. Change from Baseline in Serum Potassium (K⁺)

    Change from baseline in serum potassium. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  25. Change from Baseline in Serum Calcium (Ca²⁺)

    Change from baseline in serum calcium. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  26. Change from Baseline in Serum Magnesium (Mg²⁺)

    Change from baseline in serum magnesium. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  27. Change from Baseline in Serum Chloride (Cl-)

    Change from baseline in serum chloride. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  28. Change from Baseline in International Normalized Ratio (INR)

    Change from baseline in international normalized ratio. Unitless ratio. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  29. Change from Baseline in Activated Partial Thromboplastin Time (APTT)

    Change from Baseline in Activated Partial Thromboplastin Time (APTT)

    Time frame: Up to 56 days

  30. Change from Baseline in Prothrombin Time (PT)

    Change from baseline in prothrombin time. Measured in seconds. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  31. Change from Baseline in Fibrinogen (FIB)

    Change from baseline in fibrinogen. Measured in g/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  32. Change from Baseline in ECG Parameter: QTcF Interval

    Change from baseline in the QT interval corrected for heart rate using Fridericia's formula (QTcF). Measured in milliseconds (ms). Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.

    Time frame: Up to 56 days

  33. Change from Baseline in Systolic Blood Pressure (SBP)

    Change from baseline in systolic blood pressure. Measured in mmHg. Assessed at baseline and on Days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, and 56.

    Time frame: Up to 56 days

  34. Change from Baseline in Diastolic Blood Pressure (DBP)

    Change from baseline in diastolic blood pressure. Measured in mmHg. Assessed at baseline and on Days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, and 56.

    Time frame: Up to 56 days

  35. Change from Baseline in Pulse Rate

    Change from baseline in pulse rate. Measured in beats per minute (bpm). Assessed at baseline and on Days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, and 56.

    Time frame: Up to 56 days

  36. Peak Plasma Concentration (Cmax) - Single Dose

    Maximum observed plasma concentration following single intramuscular injection. Measured in pg/mL. Assessed at pre-dose and at 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose.

    Time frame: Up to 672 hours after first dose

  37. Time to Reach Peak Plasma Concentration (Tmax) - Single Dose

    Time to reach maximum observed plasma concentration. Measured in hours (h). Same time points as Cmax.

    Time frame: Up to 672 hours after first dose

  38. Elimination Half-Life (t½) - Single Dose

    Elimination half-life calculated as ln(2)/λz. Measured in hours (h).

    Time frame: Up to 672 hours after first dose

  39. Area Under the Curve from Time 0 to Last Measurable Concentration (AUC₀-ₗₐₛₜ) - Single Dose

    AUC using linear trapezoidal rule. Measured in h·pg/mL.

    Time frame: Up to 672 hours after first dose

  40. Area Under the Curve from Time 0 to Infinity (AUC₀-∞) - Single Dose

    Extrapolated AUC. Measured in h·pg/mL.

    Time frame: Up to 672 hours after first dose

  41. Area Under the Curve from Time 0 to 168 Hours (AUC₀-₁₆₈ₕ) - Single Dose

    AUC from 0 to 168 hours post-dose. Measured in h·pg/mL.

    Time frame: Up to 168 hours after first dose

  42. Apparent Clearance (CL/F) - Single Dose

    Dose divided by AUC₀-∞. Measured in L/h.

    Time frame: Up to 672 hours after first dose

  43. Apparent Volume of Distribution (Vz/F) - Single Dose

    Dose divided by (λz × AUC₀-∞). Measured in L.

    Time frame: Up to 672 hours after first dose

  44. Change from Baseline in CD4⁺ T Cell Count

    Change from baseline in absolute CD4⁺ T cell count. Measured in cells/μL. Assessed at baseline and at 24, 48, 72, 96, 120, 168, 240, 336, 504, 672, 1320 hours post-dose.

    Time frame: Up to 56 days

  45. Change from Baseline in CD8⁺ T Cell Count

    Change from baseline in absolute CD8⁺ T cell count. Measured in cells/μL. Same time points as CD4⁺.

    Time frame: Up to 56 days

  46. Change from Baseline in CD4/CD8 T Cell Ratio

    Change from baseline in the ratio of CD4⁺ to CD8⁺ T cells. Unitless ratio. Same time points as CD4⁺.

    Time frame: Up to 56 days

  47. Change from Baseline in Serum Interleukin-2 (IL-2) Level

    Change from baseline in serum IL-2 level. Measured in pg/mL. Assessed at baseline and at 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose.

    Time frame: Up to 672 hours (28 days)

  48. Change from Baseline in Serum Interleukin-4 (IL-4) Level

    Change from baseline in serum IL-4 level. Measured in pg/mL. Same time points as IL-2.

    Time frame: Up to 672 hours (28 days)

  49. Change from Baseline in Serum Interleukin-6 (IL-6) Level

    Change from baseline in serum IL-6 level. Measured in pg/mL. Same time points as IL-2.

    Time frame: Up to 672 hours (28 days)

  50. Change from Baseline in Serum Interleukin-8 (IL-8) Level

    Change from baseline in serum IL-8 level. Measured in pg/mL. Same time points as IL-2.

    Time frame: Up to 672 hours (28 days)

  51. Change from Baseline in Serum Interleukin-10 (IL-10) Level

    Change from baseline in serum IL-10 level. Measured in pg/mL. Same time points as IL-2.

    Time frame: Up to 672 hours (28 days)

  52. Change from Baseline in Serum Tumor Necrosis Factor-alpha (TNF-α) Level

    Change from baseline in serum TNF-α level. Measured in pg/mL. Same time points as IL-2.

    Time frame: Up to 672 hours (28 days)

  53. Change from Baseline in Serum Interferon-gamma (IFN-γ) Level

    Change from baseline in serum IFN-γ level. Measured in pg/mL. Same time points as IL-2.

    Time frame: Up to 672 hours (28 days)

  54. Number of Participants with Anti-Drug Antibodies (ADA)

    Incidence of anti-drug antibodies (ADA) against JL18008. For ADA-positive participants, titers and neutralizing antibodies (Nab) will be assessed. Assessed at baseline and at 168, 336, 504, 672, 1320 hours post-dose.

    Time frame: Up to 56 days

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Aug 2025, 13 months.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 13 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
Jun 5, 2026
StartActual
Jun 13, 2024
Primary completionActual
Aug 5, 2025
CompletionActual
Aug 5, 2025
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07629310
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Jun 13, 2024
Primary completion
Aug 5, 2025
Completion
Aug 5, 2025
Last update
Jun 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion